around its Internet site in order to determine whether the information, services, and materials on this web-site are presented in an appropriate technological format and whether it meets the needs, wants, and preferences of visitors or ''customers'' to the Internet site.

Information on the site focuses on disease prevention, health promotion, and epidemiology. The site is designed to serve the general public, persons at risk for disease, injury, and illness, and health professionals. This research will ensure that these audiences have opportunity to provide ''customer feedback'' regarding the value and effectiveness of the information, services, and products of the CDC web-site and whether these materials are easy to access, clear, and informative. The initial 60 day **Federal Register** Notice was solely for the evaluation of the National Center for HIV, STD, and TB Prevention (NCHSTP) website, but has since been modified to include the entire Agency. The total annual burden hours are 30,667.

Respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hrs)
Visitors to CDC Internet Site	184,000	1	0.1

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–10970 Filed 4–30–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

The 2000 FDA Science Forum—FDA and the Science of Safety: New Perspectives

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA), Office of Science, is announcing the following meeting entitled ''The 2000 FDA Science Forum—FDA and the Science of Safety: New Perspectives.'' The forum is devoted to the presentation and sharing of data, knowledge, and ideas among the diverse disciplines of risk management. The forum will bring FDA scientists together with industry, academia, government agencies, consumer groups, and the public to explore the scientific and practical issues related to the safety evaluation and risk management of FDA-regulated products.

Co-sponsored by FDA's Office of Science, the American Association of Pharmaceutical Scientists, FDA's Office of Women's Health, FDA's Chapter of Sigma Xi, and the Scientific Research Society.

Date and Time: The forum will be held on Monday, February 14, 2000, from 8:30 a.m. to 6 p.m., and Tuesday, February 15, 2000, from 8:30 a.m. to 5 p.m.

Location: Washington Convention Center, rms. 29 to 32 (lower level), and Hall C (upper level), 900 Ninth St. NW., Washington, DC 20001.

Contact: Susan A. Homire, Food and Drug Administration, Office of Science (HF–33), 5600 Fishers Lane, Rockville, MD 20857, 301–827–3366, e-mail ''shomire@oc.fda.gov''.

Registration: Registration information will be provided at a later date.

SUPPLEMENTARY INFORMATION: Speakers and panelists will address emerging issues in the safety assessment of foods, drugs, biologics, and medical devices. Plenary lectures and discussion groups will provide perspectives on the following topics: (1) Walking and Talking: The Art and Science of Risk Communication, (2) Contemporary Issues in Risk Assessment, (3) Postmarket Surveillance—Beyond Passive Surveillance, (4) The Food Safety Initiative—The Risk Perspective, (5) Risk and Gender Effects, and (6) Risk Assessment in Action.

Dated: April 26, 1999.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 99–11057 Filed 4–30–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: The Microbiology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on May 20, 1999, 9:45 a.m. to 6:30 p.m., and May 21, 1999, 8:30 a.m. to 4:30 p.m.

Location: Corporate Bldg., conference room 020B, 9200 Corporate Blvd., Rockville, MD.

Contact Person: Freddie M. Poole, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD. 20850, 301–594–2096, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12517. Please call the Information Line for up-to-date information on this meeting.

Agenda: On May 20, 1999, the committee will discuss and make recommendations on a premarket notification submission for a qualitative in vitro diagnostic assay intended for the detection of human cytomegalovirus (CMV) deoxyribonucleic acid (DNA) in human peripheral white blood cells and its labeling. The focus of the discussion will be the appropriate use of signal amplification terminology. The committee will also discuss, make recommendations, and vote on a premarket approval application (PMA) supplement for an in vitro diagnostic target-amplified nucleic acid probe test used for the detection of *Mycobacterium tuberculosis* complex in sediments prepared from sputum (induced or expectorated), bronchial specimens, or tracheal aspirates. The device as modified is indicated for use of acid-fast bacilli (AFB) smear negative and AFB smear positive respiratory specimens for the diagnosis of active pulmonary tuberculosis disease. On May 21, 1999, the committee will discuss, make recommendations, and vote on a PMA for an in vitro diagnostic qualitative

device to detect immunoglobulin G (IgG) antibodies to parvovirus B19 as a marker of previous infection in human serum and plasma. The IgG test is indicated for use in all women where there is a suspicion of exposure to parvovirus B19. The committee will also discuss, make recommendations, and vote on a PMA for an in vitro diagnostic qualitative device to detect IgM antibodies to parvovirus B19 in human serum and plasma. The IgM test is indicated for use in conjunction with the parvovirus B19 IgG enzyme immunoassay to determine immunological status during the first trimester of pregnancy and for the testing of pregnant women who have sonographic evidence of abnormal fetal development, such as hydrops fetalis, or who had an adverse outcome, such as fetal death or premature delivery with fetal abnormalities.

Procedure: On May 20, 1999, from 9:45 a.m. to 6:30 p.m., and on May 21, 1999, from 9:30 a.m. to 4:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 10, 1999. On May 20, 1999, oral presentations from the public will be scheduled between approximately 11:15 a.m. and 11:45 a.m. and between approximately 3:30 p.m. and 4 p.m. On May 21, 1999, oral presentations from the public will be scheduled between approximately 10:15 a.m. and 10:45 a.m. and between approximately 2 p.m. and 2:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 10, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberation: On May 21, 1999, from 8:30 a.m. to 9:30 a.m., the meeting will be closed to the public to permit discussion and review of trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)) relating to present and future agency issues.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 26, 1999.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 99–10982 Filed 4–30–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA–1101–N2]

Medicare Program; Meetings of the Competitive Pricing Demonstration Area Advisory Committee, Maricopa County, AZ

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Revised notice of meetings.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act, this notice announces meetings of the Area Advisory Committee for the Maricopa County Competitive Pricing Demonstration.

The Balanced Budget Act of 1997 (BBA) requires the Secretary of the Department of Health and Human Services (the Secretary) to establish a demonstration project under which payments to Medicare+Choice organizations in designated areas are determined in accordance with a competitive pricing methodology. The BBA requires the Secretary to appoint an Area Advisory Committee (AAC) in the designated area to advise on implementation of the project, including the marketing and pricing of the plan and other factors. AAC meetings are open to the public.

DATES: The revised schedule for meetings is May 18 and 19, 1999, from 8:30 a.m. until 5 p.m., m.s.t., and June 7 and 8, 1999, from 8:30 a.m. until 5 p.m., m.s.t.

ADDRESSES: The meetings on May 18 and 19, 1999, and June 7 and 8, 1999, will be held at the YWCA of the USA, Leadership Development Conference Center, 9440 North 25th Avenue, Phoenix, AZ 85021, (602) 944–0569.

FOR FURTHER INFORMATION CONTACT: Elizabeth C. Abbott, Regional Administrator, Health Care Financing Administration, 75 Hawthorne Street, 4th Floor, San Francisco, CA 94105, (415) 744–3501.

SUPPLEMENTARY INFORMATION: Section 4011 of the Balanced Budget Act of 1997 (BBA) requires the Secretary of the Department of Health and Human Services (the Secretary) to establish a demonstration project under which payments to Medicare+Choice organizations in designated areas are determined in accordance with a competitive pricing methodology.

Section 4012(a) of the BBA requires the Secretary to appoint a Competitive Pricing Advisory Committee to make recommendations concerning the designation of areas for the project and appropriate research designs for implementation. Once an area is designated as a demonstration site, section 4012(b) of the BBA requires the Secretary to appoint an Area Advisory Committee (AAC) to advise on the marketing and pricing of the plan in the area and other factors.

This notice announces the revised schedule of meetings of the Maricopa County AAC. We originally published a schedule of the Maricopa County AAC meetings in the March 11, 1999, issue of the **Federal Register**, at 64 FR 12173. This notice adds one day to the third AAC meeting and adds a fourth meeting. The second day of both meetings (May 19 and June 8) may be subject to cancellation.

The Maricopa County AAC will meet for the purpose of advising the Secretary on how the project will be implemented. The AAC is composed of representatives of health plans, providers, employers, and Medicare beneficiaries in the area. The AAC is composed of representatives of health plans, providers, employers, and Medicare beneficiaries in the area. The Maricopa County AAC members are: Joseph Anderson, Schaller Anderson Inc.; Rick Badger, Pacificare of Arizona; Reginald Ballantyne III, PMH Health Resources, Inc.; Donna Buelow, Arizona State Retirement System; Charles Cohen, Arizona Department of Insurance; John Hensing, M.D., Samaritan Health Systems; Mary Lynn Kasunic, Area Agency on Aging; Anne Lindeman, Governor's Advisory Council on Aging; Ben Lopez, Honeywell Corp., Thomas Marreel, William M. Mercer Associates; Anthony Mitten, Maricopa County Medical Society; Edward Munno, Jr., Intergroup of Arizona; Susan Navran, Blue Cross Blue Shield of Arizona; Erik Olsen, D.D.S., American Association of Retired Persons; Leland Peterson, Sun Health Corp.; Donna Redford, Arizona Bridge to Independent Living; Herb Rigberg, M.D., Health Services Advisory Group; Martha Taylor, Arizona SHIP; Clyde Wright, M.D., Cigna of Arizona; Arthur Pelberg, M.D., Schaller Anderson Inc.; Joseph Hanss, M.D., physician; and Phyllis Biedess, Director, AHCCCS. In accordance with section 4012(b) of the BBA, the AAC will exist for the duration of the project in the area, expected to be 5 years from the January 1, 2000, start date.

The Maricopa County AAC held its first two meetings on March 31, 1999, and April 20, 1999.

The third meeting will be extended for a second day. The third meeting will now take place on May 18 and 19, 1999.